Beneficial autoimmunity participates in the regulation of rheumatoid arthritis
- PMID: 16146738
- DOI: 10.2741/1804
Beneficial autoimmunity participates in the regulation of rheumatoid arthritis
Abstract
Antigen specific T cells and B cells recognize their target determinants by antigen specific receptors that are being rearranged in a random manner. These cells then undergo negative and positive selection processes that limit, albeit not eliminate, the escape of self-reactive T and B cells capable of eliciting autoimmune responses. The above processes are referred to as "central selection", and their outcome is the "central tolerance". Auto-reactive T and B cells escaping central tolerance are then subjected to peripheral mechanisms that restrain their auto-aggressive behavior. Different types of regulatory T cells are key players in maintaining actively induced peripheral tolerance. In patients suffering from various autoimmune disorders autoreactive T and/or B cells that escaped central tolerance also circumvented regulatory T cells that could, potentially, eradicate their pathogenicity in the periphery. We have found an additional regulatory mechanism that restrains the harmful activity of these cells at that time. It includes autoimmune B cells that produce neutralizing autoantibodies against numerous inflammatory mediators, mostly cytokines and chemokines, which participate in destructive autoimmunity. These autoantibodies restrain the harmful consequences of inflammatory autoimmune conditions such as in rheumatoid arthritis. Interestingly, this antibody production is elicited during autoimmune diseases, and to a much lesser extent during local inflammation. The specificity of this response is highly restricted to determinants with minimal cross reactivity to other known gene products. Thus, the immune system allows selective breakdown of tolerance in autoimmune conditions. The findings that this beneficial response is turned on by the autoimmune condition, and then regulated by its progression further imply for the existence of a programmed regulatory response of "beneficial autoimmunity". In the current review we describe how this mechanism was discovered in experimental models of rheumatoid arthritis and multiple sclerosis, demonstrate its importance in the natural regulation of these diseases, and finally explore its relevance to human diseases.
Similar articles
-
Autoantibodies to Chemokines and Cytokines Participate in the Regulation of Cancer and Autoimmunity.Front Immunol. 2018 Mar 29;9:623. doi: 10.3389/fimmu.2018.00623. eCollection 2018. Front Immunol. 2018. PMID: 29651292 Free PMC article. Review.
-
Induction of protective therapy for autoimmune diseases by targeted DNA vaccines encoding pro-inflammatory cytokines and chemokines.Curr Opin Mol Ther. 2004 Feb;6(1):27-33. Curr Opin Mol Ther. 2004. PMID: 15011778 Review.
-
Gene therapy for T cell-mediated autoimmunity: teaching the immune system how to restrain its own harmful activities by targeted DNA vaccines.Isr Med Assoc J. 2000 Jul;2 Suppl:63-8. Isr Med Assoc J. 2000. PMID: 10909420 Review.
-
B cells participate in tolerance and autoimmunity through cytokine production.Autoimmunity. 2014 Feb;47(1):1-12. doi: 10.3109/08916934.2013.856006. Epub 2013 Nov 18. Autoimmunity. 2014. PMID: 24245950 Review.
-
The role of B lymphocytes in the progression from autoimmunity to autoimmune disease.Clin Immunol. 2013 Jan;146(1):34-45. doi: 10.1016/j.clim.2012.10.005. Epub 2012 Oct 22. Clin Immunol. 2013. PMID: 23202542 Review.
Cited by
-
Anti-cytokine autoantibodies: mechanistic insights and disease associations.Nat Rev Immunol. 2024 Mar;24(3):161-177. doi: 10.1038/s41577-023-00933-2. Epub 2023 Sep 19. Nat Rev Immunol. 2024. PMID: 37726402 Review.
-
Biphasic Production of Anti-ApoB100 Autoantibodies in Obese Humans and Mice.Pharmaceuticals (Basel). 2021 Apr 4;14(4):330. doi: 10.3390/ph14040330. Pharmaceuticals (Basel). 2021. PMID: 33916621 Free PMC article.
-
Analysis of Hepatic Lipid Metabolism and Immune Function During the Development of Collagen-Induced Arthritis.Front Immunol. 2022 Jun 16;13:901697. doi: 10.3389/fimmu.2022.901697. eCollection 2022. Front Immunol. 2022. PMID: 35784282 Free PMC article.
-
Do antiphospholipid antibodies develop for a purpose?Curr Rheumatol Rep. 2006 Apr;8(2):109-13. doi: 10.1007/s11926-006-0050-2. Curr Rheumatol Rep. 2006. PMID: 16569369 Review.
-
Reproducibility of fluid-phase measurements in PBS-treated sputum supernatant of healthy and stable COPD subjects.Int J Chron Obstruct Pulmon Dis. 2019 Apr 11;14:835-852. doi: 10.2147/COPD.S187661. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31043775 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical